首页 > 市场调查报告书 > 医疗设备

生技设备

市场调查报告书

商品编码

1452444

蛋白质工程市场-按产品（仪器、试剂、软体和服务）、技术（非理性、理性）、蛋白质（胰岛素、单株抗体、疫苗、生长因子、凝血因子、干扰素）、最终用途-全球预测， 2024年- 2032

Protein Engineering Market - By Product (Instrument, Reagent, Software & Services), Technology (Irrational, Rational), Protein (Insulin, Monoclonal Antibody, Vaccine, Growth Factor, Coagulation Factor, Interferon), End-use-Global Forecast, 2024-2032

出版日期: 2024年02月01日 | 出版商:

Global Market Insights Inc. | 英文 155 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在新创公司大量投资的推动下，全球蛋白质工程市场规模预计 2024 年至 2032 年间CAGR将超过 15.9%。创新企业的涌入为该行业注入了活力，推动了基于蛋白质的疗法、工业酶和生物催化剂的进步。例如，2023 年11 月，荷兰-瑞士新创公司Cradle 在第一轮融资中获得了2,400 万美元，以推进其生成人工智慧(GenAI) 和合成生物学平台，用于製作基于蛋白质的疗法和其他化合物。

新创公司日益增长的兴趣也反映出人们认识到蛋白质工程在应对医疗保健和工业挑战方面的关键作用。这些投资的升级可能为变革性研究培育肥沃的土壤，有望重塑医学、生物技术等领域的模式。

整个市场分为产品、技术、蛋白质类型、最终用途和地区。

就产品而言，从2024年到2032年，仪器领域的蛋白质工程产业复合CAGR预计将达到15.9%。对于从事新型蛋白质疗法和工业酵素开发的研究人员和科学家来说，尖端工具已变得不可或缺。随着技术的快速进步，对高通量筛选系统、蛋白质纯化设备和分析仪器以简化蛋白质工程流程的需求不断增长。製造商日益关注创新以满足不断变化的需求，这将进一步推动该细分市场的成长。

基于技术，来自非合理蛋白质设计领域的蛋白质工程市场收入从 2024 年到 2032 年将实现 15.8% 的CAGR。这种创新方法涉及偏离传统的蛋白质结构原理，创造新的功能和特性。研究人员越来越多地探索不合理的蛋白质设计，为治疗和工业过程中的各种应用开发客製化的解决方案。人们对专业工具、计算模型和专业知识的兴趣日益浓厚，将促进该细分市场的扩张。

欧洲蛋白质工程市场从 2024 年到 2032 年将呈现 16% 的CAGR。由于高度重视生物技术和医疗保健创新，一些欧洲国家正在推动基于蛋白质的疗法、工业酶和生物催化剂的进步。研究机构和生物技术公司的强大生态系统以及政府倡议的涌入正在支持整个地区的蛋白质工程研究和开发。对尖端技术和合作项目的投资激增也将有助于区域产业的成长。例如，2024 年 3 月，德国着名生物公司 BRAIN Biotech AG 和先进材料领域的全球领导者 AMSilk GmbH 宣布成功完成合作开发工作的初始阶段。经过一年的共同努力，他们已经实现了天然结构蛋白的显着优化。

产业生态系统分析
产业影响力
- 成长动力
  - 蛋白质缺乏疾病的盛行率上升
  - 蛋白质药物的采用率高于非蛋白质药物
  - 增加生物製药产业的研发活动
  - 蛋白质工程的融资机会不断增加
- 产业陷阱与挑战
  - 蛋白质工程技术成本高
  - 合格研究人员的数量有限
成长潜力分析
技术景观
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
竞争定位矩阵
战略展望矩阵

第 5 章：市场估计与预测：按产品分类，2018 年 - 2032 年

主要趋势
仪器
试剂
软体与服务

第 6 章：市场估计与预测：按技术划分，2018 年 - 2032 年

主要趋势
不合理的蛋白质设计
合理的蛋白质设计

第 7 章：市场估计与预测：按蛋白质类型，2018 - 2032

主要趋势
胰岛素
单株抗体
疫苗
生长因子
凝血因子
干扰素
其他蛋白质类型

第 8 章：市场估计与预测：按最终用途，2018 - 2032 年

主要趋势
学术研究机构
合约研究组织 (CRO)
製药和生物技术公司

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

Agilent Technologies, Inc.
Amgen Inc.
Bio-Rad Laboratories, Inc.
Bristol Myers Squibb Company
Bruker Corporation
Danaher Corporation
Genentech, Inc.
Integrated DNA Technologies, Inc.
Lonza Group
Merck KGaA
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Incorporated

简介目录

Product Code: 8008

Global Protein Engineering Market size is projected to accrue over 15.9% CAGR between 2024 and 2032, propelled by substantial investments from startups. The influx of innovative ventures is injecting dynamism into the industry, driving advancements in protein-based therapeutics, industrial enzymes, and biocatalysts. For instance, in November 2023, Dutch-Swiss startup Cradle secured 24 million in its first-round financing to advance its generative AI (GenAI) and synthetic biology platform for crafting protein-based therapeutics and other compounds.

The burgeoning interest from startups also reflects the recognition of the pivotal role of protein engineering in addressing healthcare and industrial challenges. The escalation of these investments is likely to foster a fertile ground for transformative research, promising to reshape the landscape of medicine, biotechnology, and beyond.

The overall market is classified into product, technology, protein type, end-use and region.

In terms of product, the protein engineering industry from the instruments segment is set to record 15.9% CAGR from 2024 to 2032. Cutting-edge tools have grown indispensable for researchers and scientists engaged in the development of novel protein-based therapeutics and industrial enzymes. With the rapid technology advancements, there is a growing need for high-throughput screening systems, protein purification equipment, and analytical instruments to streamline the protein engineering process. The surging focus of manufacturers on innovations to meet the evolving needs will further drive the segment growth.

Based on technology, the protein engineering market revenue from the irrational protein design segment will register a 15.8% CAGR from 2024 to 2032. This innovative approach involves deviating from conventional protein structure principles to create novel functionalities and properties. Researchers are increasingly exploring irrational protein designs to develop tailor-made solutions for diverse applications in therapeutics, and industrial processes. The rising interest in specialized tools, computational models, and expertise will add to the segment expansion.

Europe protein engineering market will showcase 16% CAGR from 2024 to 2032. With a strong focus on biotechnology and healthcare innovation, several European countries are driving advancements in protein-based therapeutics, industrial enzymes, and biocatalysts. The robust ecosystem of research institutions and biotech companies along with the influx of government initiatives are supporting protein engineering research and development across the region. The surging investments in cutting-edge technologies and collaborative projects will also contribute to the regional industry growth. For instance, in March 2024, BRAIN Biotech AG, a prominent German biologizing company, and AMSilk GmbH, a global leader in advanced materials, announced the successful conclusion of the initial phase of their collaborative development effort. Following a year of joint endeavors, they have achieved significant optimization of a natural structural protein.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of protein-deficient diseases
  - 3.2.1.2 Increase in adoption of protein drugs over non-protein drugs
  - 3.2.1.3 Increasing research & development activities in the biopharmaceutical industry
  - 3.2.1.4 Growing funding opportunities for protein engineering
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High costs of protein engineering techniques
  - 3.2.2.2 Limited availability of qualified researchers
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutess
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategic outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Instruments
5.3 Reagents
5.4 Software & services

Chapter 6 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Irrational protein design
6.3 Rational protein design

Chapter 7 Market Estimates and Forecast, By Protein Type, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Insulin
7.3 Monoclonal antibodies
7.4 Vaccines
7.5 Growth factors
7.6 Coagulation factors
7.7 Interferon
7.8 Other protein types

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Academic research institutes
8.3 Contract research organizations (CROs)
8.4 Pharmaceutical & biotechnology companies

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa